Ximelagatran (Standard)
Ximelagatran (Standard) is the analytical standard of Ximelagatran (HY-10787). This product is intended for research and analytical applications. Ximelagatran (H 376/95) is an orally active thrombin inhibitor that selectively and competitively inhibits both free and clot-bound thrombin. Ximelagatran is an anticoagulant agent with a rapid onset of anticoagulant effect, predictable, dose-dependent pharmcoKinetics and pharmacodynamics.
For research use only. We do not sell to patients.
- Purity: 98%
- CAS No.: 192939-46-1
- Formula: C24H35N5O5
- Molecular Weight:473.57
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Purity & Documentation
-
Help & FAQs
-
HY-10787
Ximelagatran
-
HY-10163
Dabigatran
-
HY-B0375
Argatroban
-
HY-10274A
Dabigatran etexilate mesylate
-
HY-10163R
Dabigatran (Standard)
-
HY-10274
Dabigatran etexilate
-
HY-P1929
Bivalirudin
-
HY-10277
Odiparcil
-
HY-B0375A
Argatroban monohydrate
-
HY-17378
Dabigatran ethyl ester
-
HY-B0375R
Argatroban (Standard)
-
HY-114164
Thrombin (MW 37kDa)
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 192939-46-1
-
Molecular Weight 473.57
-
Formula C24H35N5O5
-
SMILES
O=C([C@@H]1CCN1C([C@@H](C2CCCCC2)NCC(OCC)=O)=O)NCC3=CC=C(C=C3)/C(N)=N/O
-
Synonyms
H 376/95 (Standard)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Colwell CW Jr, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost. 2003 Oct;1(10):2119-30. [Content Brief]
[2]. Gao JH, et al. Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis. Medicine (Baltimore). 2017 Oct;96(40):e8059. [Content Brief]
[3]. Francis CW, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003 Oct 30;349(18):1703-12. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Ximelagatran (Standard) Related Classifications
HY-10787R Related Classifications
Powered by Bioz